Dendreon says prostate drug

pabigy.wordpress.com
According to Dendreon, 512 patients were enrolled inthe study, whic tested Provenge on men with metastatic androgen-independentt prostate cancer. The drug, according to is designed to engagea patient’s own immunw system against cancer. “The successful outcomw from the … study provides validation of the long-pursuexd goal of harnessing the human immune system againsta patient’s own said Dr. Mitchell Gold, president and CEO of in a statement. One Seattle stock analyst who coveres the companysaid “it’s difficult not to be with the study’s results.
“It’s a clear win for Dendreon employees, urologists, long investors, cancer researchers, and the Seattle biotech community,” wroted Paul Latta of , in a note to investors.